NewAmsterdam Pharma Co N.V.NAMSWEarnings & Financial Report
Kite Pharma, Inc. is an American biotechnology company that develops cancer immunotherapy products with a primary focus on genetically engineered autologous CAR T cell therapy - a cell-based therapy which relies on chimeric antigen receptors and T cells. Founded in 2009, and based in Santa Monica, California, it was acquired by Gilead Sciences in 2017.
NAMSW Q4 2025 Key Financial Metrics
Revenue
$32.0K
Gross Profit
N/A
Operating Profit
$-66.0M
Net Profit
$-74.9M
Gross Margin
N/A
Operating Margin
-206187.5%
Net Margin
-234134.4%
YoY Growth
-99.7%
EPS
$-0.62
Financial Flow
NewAmsterdam Pharma Co N.V. Q4 2025 Financial Summary
NewAmsterdam Pharma Co N.V. reported revenue of $32.0K for Q4 2025, with a net profit of $-74.9M (-234134.4% margin). Cost of goods sold was N/A, operating expenses totaled N/A.
Key Financial Metrics
| Total Revenue | $32.0K |
|---|---|
| Net Profit | $-74.9M |
| Gross Margin | N/A |
| Operating Margin | -206187.5% |
| Report Period | Q4 2025 |
NewAmsterdam Pharma Co N.V. Annual Revenue by Year
NewAmsterdam Pharma Co N.V. annual revenue history includes year-by-year totals (for example, 2025 revenue was $22.5M).
| Year | Annual Revenue |
|---|---|
| 2025 | $22.5M |
| 2024 | $45.6M |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.4M | $2.3M | $29.1M | $12.8M | $3.0M | $19.1M | $348000 | $32000 |
| YoY Growth | -83.8% | 32.7% | N/A | N/A | 112.6% | 740.1% | -98.8% | -99.7% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $488.5M | $446.7M | $439.2M | $864.6M | $818.4M | $815.1M | $786.4M | $769.3M |
| Liabilities | $76.7M | $59.3M | $60.3M | $107.1M | $41.0M | $36.6M | $58.4M | $85.9M |
| Equity | $411.8M | $387.4M | $378.9M | $757.5M | $777.4M | $778.5M | $728.1M | $683.4M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-54.6M | $-54.0M | $-12.5M | $-37.5M | $-36.5M | $-37.7M | $-32.8M | $-40.9M |
